<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="10.1002/agm2.12102AGM212102 : Guidelines and Consensus: Guidelines and Consensus Recommendations for" exact="influenza" post="and Streptococcus pneumoniae vaccination in elderly people in China"/>
 <result pre="the original work is properly cited.file:AGM2-3-1.pdf Abstract Abstract Influenza and" exact="pneumonia" post="can be prevented by vaccination, but they remain major"/>
 <result pre="age�?related diseases. In most areas of China, the rates of" exact="influenza" post="and pneumococcal vaccination are relatively low and public awareness"/>
 <result pre="of vaccination remains insufficient. Thus, it is essential to recommend" exact="influenza" post="and Streptococcus pneumoniae vaccination to elderly people in clinical"/>
 <result pre="Advisory Committee on Immunization Practices, we propose official recommendations for" exact="influenza" post="and S pneumoniae vaccination in elderly people in China."/>
 <result pre="S pneumoniae vaccination in elderly people in China. elderly people" exact="influenza" post="Streptococcus pneumoniae vaccination Funding Merck Sharp and Dohme 10.13039/100009947"/>
 <result pre="Respiratory Group and Chinese Society of Geriatrics . Recommendations for" exact="influenza" post="and Streptococcus pneumoniae vaccination in elderly people in China."/>
 <result pre="1. 1 INTRODUCTION Although they can be prevented by vaccination," exact="influenza" post="and pneumonia are major causes of morbidity and mortality"/>
 <result pre="INTRODUCTION Although they can be prevented by vaccination, influenza and" exact="pneumonia" post="are major causes of morbidity and mortality in age�?related"/>
 <result pre="mortality in age�?related disease. In most areas of China, the" exact="influenza" post="and pneumococcal vaccination rates are relatively low and public"/>
 <result pre="clinicians—should make systematic and scientific efforts to popularize knowledge of" exact="influenza" post="and Streptococcus pneumonia vaccination and aim towards standardized vaccination"/>
 <result pre="and scientific efforts to popularize knowledge of influenza and Streptococcus" exact="pneumonia" post="vaccination and aim towards standardized vaccination recommendations and practices."/>
 <result pre="primarily based on the epidemiology and disease burden associated with" exact="influenza" post="and pneumococcal diseases, and the evidence of vaccine safety"/>
 <result pre="and the US Advisory Committee on Immunization Practices (ACIP). Herein," exact="influenza" post="and S pneumonia vaccination of elderly people in China"/>
 <result pre="Advisory Committee on Immunization Practices (ACIP). Herein, influenza and S" exact="pneumonia" post="vaccination of elderly people in China is advocated to"/>
 <result pre="that population. 2 INFLUENZA VACCINE 2.1 Etiology and epidemiology of" exact="influenza" post="Influenza viruses belong to the family Orthomyxoviridae. Based on"/>
 <result pre="divided into types A, B, C, and D. Type A" exact="influenza" post="viruses are further divided into various subtypes based on"/>
 <result pre="the surface antigens hemagglutinin (H1�?H18) and neuraminidase (N1�?N11). Type B" exact="influenza" post="and two influenza A subtypes, A/H3N2 and A/H1N1, are"/>
 <result pre="hemagglutinin (H1�?H18) and neuraminidase (N1�?N11). Type B influenza and two" exact="influenza" post="A subtypes, A/H3N2 and A/H1N1, are considered the main"/>
 <result pre="and A/H1N1, are considered the main pathogens responsible for human" exact="influenza" post="epidemics.1, 2, 3 The epidemiological characteristics of influenza viruses"/>
 <result pre="for human influenza epidemics.1, 2, 3 The epidemiological characteristics of" exact="influenza" post="viruses include their capacity for antigenic variability and sudden"/>
 <result pre="and nursing homes.4 The dominant strains and activity intensity of" exact="influenza" post="viruses in different periods and regions exhibit distinct characteristics."/>
 <result pre="exhibit distinct characteristics. Climate factors are the strongest predictors of" exact="influenza" post="seasonality, including the lowest temperature, hours of sunshine, and"/>
 <result pre="and maximum rainfall. Low temperature is a predictor of winter" exact="influenza" post="occurrence and annual cyclical intensity in northern China, whereas"/>
 <result pre="annual cyclical intensity in northern China, whereas in southern China," exact="influenza" post="activity is related mainly to rainfall. That knowledge can"/>
 <result pre="upon when devising strategies for determining the optimal times for" exact="influenza" post="vaccination. In 2013, Yu et al5 demonstrated that the"/>
 <result pre="2013, Yu et al5 demonstrated that the annual periodicity of" exact="influenza" post="A epidemics increases with latitude, and that their spatial"/>
 <result pre="most of the southwestern regions (latitudes 27.4�?31.3°N) experience dominant semi�?annual" exact="influenza" post="A periodicity with peaks in January and February, and"/>
 <result pre="in January and February, and from June to August. Conversely," exact="influenza" post="B activity predominantly occurs in the colder months throughout"/>
 <result pre="colder months throughout most of China. 2.2 Disease burden of" exact="influenza" post="in elderly people Influenza can result in serious complications,"/>
 <result pre="in elderly people Influenza can result in serious complications, including" exact="viral pneumonia," post="secondary bacterial pneumonia, encephalitis, and myocarditis, all of which"/>
 <result pre="Influenza can result in serious complications, including viral pneumonia, secondary" exact="bacterial pneumonia," post="encephalitis, and myocarditis, all of which can aggravate underlying"/>
 <result pre="complications and malnutrition, elderly people are a high�?risk population for" exact="influenza" post="virus infection. Influenza infection in elderly people is associated"/>
 <result pre="in the southern cities. Approximately 86% of deaths associated with" exact="influenza" post="reportedly occur in people aged ≥ 65 years. The"/>
 <result pre="vaccine development Influenza vaccine development has involved the isolation of" exact="influenza" post="viruses, identification of changes in circulating strains, and refinement"/>
 <result pre="Research in London began to develop the first live attenuated" exact="influenza" post="vaccine by successfully isolating the first influenza virus. The"/>
 <result pre="first live attenuated influenza vaccine by successfully isolating the first" exact="influenza" post="virus. The United States and the United Kingdom subsequently"/>
 <result pre="subsequently successfully developed the first monovalent type A (H1N1) inactivated" exact="influenza" post="vaccine. Since then, influenza vaccine development has progressed remarkably"/>
 <result pre="first monovalent type A (H1N1) inactivated influenza vaccine. Since then," exact="influenza" post="vaccine development has progressed remarkably rapidly. In 1942, a"/>
 <result pre="vaccine development has progressed remarkably rapidly. In 1942, a bivalent" exact="influenza" post="vaccine was developed after the detection of influenza B"/>
 <result pre="a bivalent influenza vaccine was developed after the detection of" exact="influenza" post="B virus. In 1978, when influenza A virus (H1N1"/>
 <result pre="after the detection of influenza B virus. In 1978, when" exact="influenza" post="A virus (H1N1 and H3N2) and influenza B virus"/>
 <result pre="In 1978, when influenza A virus (H1N1 and H3N2) and" exact="influenza" post="B virus were simultaneously prevalent, a trivalent influenza vaccine"/>
 <result pre="H3N2) and influenza B virus were simultaneously prevalent, a trivalent" exact="influenza" post="vaccine type A(H1N1)/A(H3N2)/B was introduced.10 In the late 1980s,"/>
 <result pre="A(H1N1)/A(H3N2)/B was introduced.10 In the late 1980s, two strains of" exact="influenza" post="B virus were discovered, Victoria and Yamagata, which were"/>
 <result pre="mismatch between the actual circulating strains and vaccine candidates for" exact="influenza" post="B vaccine strains in component vaccines.11 Therefore, since 2012,"/>
 <result pre="since 2012, recommendations issued by the WHO with regard to" exact="influenza" post="vaccine composition have included both the Victoria and Yamagata"/>
 <result pre="that are updated annually, which constitutes a tetravalent vaccine. Most" exact="influenza" post="vaccines are manufactured via virus propagation in eggs or"/>
 <result pre="split vaccine has become mainstream since the first split virion" exact="influenza" post="vaccine was launched in 1968. Since then, a subunit"/>
 <result pre="immunogenicity of subunit vaccines, some manufacturers have also developed adjuvant" exact="influenza" post="vaccines. In 2009, high�?dose inactivated influenza vaccines were first"/>
 <result pre="have also developed adjuvant influenza vaccines. In 2009, high�?dose inactivated" exact="influenza" post="vaccines were first used in the United States for"/>
 <result pre="over.12 Influenza vaccines that are currently available internationally include inactivated" exact="influenza" post="vaccine (IIV), recombinant influenza vaccine (RIV), and live attenuated"/>
 <result pre="are currently available internationally include inactivated influenza vaccine (IIV), recombinant" exact="influenza" post="vaccine (RIV), and live attenuated influenza vaccine, all of"/>
 <result pre="influenza vaccine (IIV), recombinant influenza vaccine (RIV), and live attenuated" exact="influenza" post="vaccine, all of which are available in trivalent or"/>
 <result pre="three types: whole�?virus vaccine, split�?virus vaccine, and subunit vaccine. The" exact="influenza" post="vaccines currently used in China are all trivalent IIVs"/>
 <result pre="humoral and cellular immune responses in humans. In humoral immunity," exact="influenza" post="vaccines mainly induce the production of antibodies against influenza"/>
 <result pre="immunity, influenza vaccines mainly induce the production of antibodies against" exact="influenza" post="virus surface glycoproteins. Serum antibody levels usually peak within"/>
 <result pre="glycoproteins. Serum antibody levels usually peak within 2�?4 weeks after" exact="influenza" post="virus infection or vaccination, but in elderly people it"/>
 <result pre="response in elderly people is comparatively lower. Adjuvants and high�?dose" exact="influenza" post="vaccines have been explored to improve vaccine immunogenicity. Adjuvants"/>
 <result pre="a standard�?dose vaccine, high�?dose IIV3 (IIV3�?HD) improves antibody responses to" exact="influenza" post="in adults aged 65 years or older.17 The protective"/>
 <result pre="adults aged 65 years or older.17 The protective effect of" exact="influenza" post="vaccine lasts approximately 6�?8 months18 then wanes over time,"/>
 <result pre="reduced by 1 year after vaccination. The WHO recommends that" exact="influenza" post="vaccine components be updated annually because of the ever�?changing"/>
 <result pre="be updated annually because of the ever�?changing antigenic nature of" exact="influenza" post="virus. To provide maximum protection for the vaccinated population,"/>
 <result pre="is still recommended that recipients vaccinate again in the current" exact="influenza" post="season, as the antibody titers in most vaccine recipients"/>
 <result pre="recipients decline substantially after a year, even if the antigenic" exact="influenza" post="vaccine components are exactly the same as those in"/>
 <result pre="Application benefits Vaccination is currently an effective way to prevent" exact="influenza" post="in elderly people. In a meta�?analysis of data derived"/>
 <result pre="a meta�?analysis of data derived from elderly people in China," exact="influenza" post="vaccine had a 53% prevention effect on influenza�?like illness"/>
 <result pre="elderly people over the age of 60 years who received" exact="influenza" post="vaccine in Beijing, and in that analysis, influenza vaccination"/>
 <result pre="who received influenza vaccine in Beijing, and in that analysis," exact="influenza" post="vaccination was associated with reduced likelihood of developing &quot;colds�?"/>
 <result pre="(49.54%), &quot;respiratory diseases�? (64.54%), and &quot;chronic diseases�? (38.82%). Vaccination against" exact="influenza" post="can effectively reduce the number of influenza�?related emergency medical"/>
 <result pre="people. Many elderly people have chronic diseases, such as diabetes," exact="chronic obstructive pulmonary disease," post="coronary heart disease, and cerebrovascular disease, and influenza vaccination"/>
 <result pre="chronic diseases, such as diabetes, chronic obstructive pulmonary disease, coronary" exact="heart disease," post="and cerebrovascular disease, and influenza vaccination may have a"/>
 <result pre="obstructive pulmonary disease, coronary heart disease, and cerebrovascular disease, and" exact="influenza" post="vaccination may have a flow�?on effect of reducing hospitalization"/>
 <result pre="with a 27% reduction in the risk of hospitalization for" exact="pneumonia" post="or influenza and a 48% reduction in the risk"/>
 <result pre="27% reduction in the risk of hospitalization for pneumonia or" exact="influenza" post="and a 48% reduction in the risk of death.21"/>
 <result pre="Fireman et al22 examined mortality before, during, and after nine" exact="influenza" post="seasons in relation to time�?varying vaccination status in an"/>
 <result pre="from 1996 to 2005, including 20 484 deaths during laboratory�?defined" exact="influenza" post="seasons. The overall estimated vaccine effectiveness against all�?cause mortality"/>
 <result pre="seasons. The overall estimated vaccine effectiveness against all�?cause mortality during" exact="influenza" post="seasons was 4.6%. Nichol et al23 studied 140 055"/>
 <result pre="Nichol et al23 studied 140 055 subjects in a 1998�?1999" exact="influenza" post="season cohort and 146 328 in a 1999�?2000 influenza"/>
 <result pre="1998�?1999 influenza season cohort and 146 328 in a 1999�?2000" exact="influenza" post="season cohort, and reported that vaccination against influenza was"/>
 <result pre="a 1999�?2000 influenza season cohort, and reported that vaccination against" exact="influenza" post="was associated with: reductions in the risks of hospitalization"/>
 <result pre="disease, cerebrovascular disease (1998�?1999 season 16%, 1999�?2000 season 23%), and" exact="pneumonia" post="or influenza (1998�?1999 season 32%, 1999�?2000 season 29%); and"/>
 <result pre="disease (1998�?1999 season 16%, 1999�?2000 season 23%), and pneumonia or" exact="influenza" post="(1998�?1999 season 32%, 1999�?2000 season 29%); and reductions in"/>
 <result pre="season 50%). Influenza vaccination can reduce medical expenses imposed by" exact="influenza" post="itself and associated acute exacerbations of chronic diseases, which"/>
 <result pre="Control and Prevention analyzed the efficacy and cost�?benefit analysis of" exact="influenza" post="vaccination in 665 people aged over 60 years in"/>
 <result pre="et al25 performed a meta�?analysis of health economic evaluations of" exact="influenza" post="vaccination around the world that included both high�?income and"/>
 <result pre="that included both high�?income and middle�?income countries, and concluded that" exact="influenza" post="vaccination was cost�?effective. Wang et al26 demonstrated that influenza"/>
 <result pre="that influenza vaccination was cost�?effective. Wang et al26 demonstrated that" exact="influenza" post="vaccination reduced hospitalization costs by US $1282.60 compared with"/>
 <result pre="by US $1282.60 compared with patients who had not undergone" exact="influenza" post="vaccination. 2.4.3 Safety Inoculation with IIVs is generally safe"/>
 <result pre="pain, erythema, and swelling.13 Vaccination recipients without a history of" exact="influenza" post="vaccine antigen exposure may experience transient symptoms, such as"/>
 <result pre="frequently in adults.32 Those who have experienced severe anaphylaxis after" exact="influenza" post="vaccination should not seek revaccination. It has been reported"/>
 <result pre="to develop Guillain�?Barré syndrome,33, 34 but no direct relationships between" exact="influenza" post="vaccination and the syndrome have been reported.35 According to"/>
 <result pre="million doses from 1990 to 2005.36 2.5 Current status of" exact="influenza" post="vaccination in elderly people in China In China, the"/>
 <result pre="influenza vaccination in elderly people in China In China, the" exact="influenza" post="vaccination rate remains low. Yang et al37 reported that"/>
 <result pre="vaccination rate remains low. Yang et al37 reported that the" exact="influenza" post="vaccination rate in China’s total population was only 1.9%"/>
 <result pre="60 years from nine cities was 4.3% in the 2011�?2012" exact="influenza" post="season. In efforts to increase the influenza vaccination rate,"/>
 <result pre="in the 2011�?2012 influenza season. In efforts to increase the" exact="influenza" post="vaccination rate, some cities (for example Zhuhai and Ningbo)"/>
 <result pre="cities (for example Zhuhai and Ningbo) now include reimbursement of" exact="influenza" post="vaccination costs as part of medical or social insurance."/>
 <result pre="and Prevention, after the implementation of publicly funded vaccination, the" exact="influenza" post="vaccination rate in elderly people was approximately 50% from"/>
 <result pre="higher than it had previously been.39 2.6 Worldwide guidelines on" exact="influenza" post="vaccination in elderly people National influenza vaccine guidelines recommend"/>
 <result pre="2.6 Worldwide guidelines on influenza vaccination in elderly people National" exact="influenza" post="vaccine guidelines recommend that elderly people should receive one"/>
 <result pre="influenza vaccine guidelines recommend that elderly people should receive one" exact="influenza" post="vaccination every year.6, 12, 40, 41, 42 The IIV"/>
 <result pre="standard TIV or a high dose of TIV, a quadrivalent" exact="influenza" post="vaccine, or a trivalent adjuvanted influenza vaccine.6 The Australian"/>
 <result pre="of TIV, a quadrivalent influenza vaccine, or a trivalent adjuvanted" exact="influenza" post="vaccine.6 The Australian and New Zealand Geriatrics Association, the"/>
 <result pre="in Europe recommend standard doses of TIV or quadrivalent inactivated" exact="influenza" post="vaccines.41 2.7 Recommendations for influenza vaccination strategies in elderly"/>
 <result pre="of TIV or quadrivalent inactivated influenza vaccines.41 2.7 Recommendations for" exact="influenza" post="vaccination strategies in elderly people in China Trivalent IIVs"/>
 <result pre="and are currently approved for use in China. Quadrivalent inactivated" exact="influenza" post="vaccines are about to be approved. Other IIVs, such"/>
 <result pre="Vaccination and the Vaccination Practice (http://www.gov.cn/yjgl/2005-10/14/content_77713.htm). 2.7.1 Target population and" exact="influenza" post="vaccination schedule Adults aged &amp;gt; 60 years should receive"/>
 <result pre="&amp;gt; 60 years should receive an annual TIV before the" exact="influenza" post="season starts. To achieve better protection, elderly people should"/>
 <result pre="achieve better protection, elderly people should be vaccinated annually because" exact="influenza" post="viruses are prone to rapid antigenic mutation. When vaccine"/>
 <result pre="health institutions, nursing homes, and sanitariums. Vaccinating health�?care workers against" exact="influenza" post="not only protects them and keeps health services running"/>
 <result pre="only protects them and keeps health services running during the" exact="influenza" post="season, it also reduces the chances of them transmitting"/>
 <result pre="upper arm is the preferred administration site. In patients with" exact="thrombocytopenia" post="or other hemorrhagic disorders who are at a comparatively"/>
 <result pre="allergic to any active components, adjuvants, or trace ingredients in" exact="influenza" post="vaccines, such as eggs (ovalbumin or chicken protein), neomycin,"/>
 <result pre="treated with natural cooling or medication. Some recipients may experience" exact="urticaria" post="after vaccination. A very small minority of recipients reportedly"/>
 <result pre="conditions they have or immunosuppressant medications they are taking before" exact="influenza" post="vaccination. To prevent allergic reactions after vaccination, appropriate monitoring"/>
 <result pre="should be prepared in advance. Vaccination can prevent infection by" exact="influenza" post="strains contained in the vaccine from 2 to 3"/>
 <result pre="3 weeks after vaccination. Notably, however, people may still develop" exact="influenza" post="if they are exposed to the virus before or"/>
 <result pre="to the virus before or immediately after vaccination because the" exact="influenza" post="incubation period is typically several days. Different injection sites"/>
 <result pre="typically several days. Different injection sites should be used when" exact="influenza" post="vaccination is administered in conjunction with other vaccines. Vaccination"/>
 <result pre="have developed Guillain�?Barré syndrome within 6 weeks of a previous" exact="influenza" post="vaccination. All vaccine recipients should be kept under observation"/>
 <result pre="are associated with high mortality. Streptococcus pneumoniae results in bacteremia" exact="pneumonia" post="in approximately 20% of cases. Reportedly, up to 30"/>
 <result pre="although the proportions of pneumococcal infections in cases of community�?acquired" exact="pneumonia" post="(CAP) reportedly differ in different regions, varying from 28.0%"/>
 <result pre="tract infection, antibiotic use, and hospitalization frequency in patients with" exact="chronic obstructive pulmonary disease" post="and coronary heart diseases, and reduce lower respiratory tract"/>
 <result pre="1006 adults aged ≥ 55 years, the incidence of all�?cause" exact="pneumonia" post="and pneumococcal pneumonia was significantly lower in a vaccinated"/>
 <result pre="≥ 55 years, the incidence of all�?cause pneumonia and pneumococcal" exact="pneumonia" post="was significantly lower in a vaccinated group than in"/>
 <result pre="group than in a placebo group, and mortality from pneumococcal" exact="pneumonia" post="was significantly higher in the placebo group. In a"/>
 <result pre="Moberley et al,69 the PPSV23 vaccine was effective for preventing" exact="pneumonia" post="and IPD in adults, and it was effective for"/>
 <result pre="and 1.06%. The combined administration of pneumococcal polysaccharide vaccination and" exact="influenza" post="vaccination has a partially additive benefit. A meta�?analysis on"/>
 <result pre="reported in 2016 indicated that combined pneumococcal polysaccharide vaccination and" exact="influenza" post="vaccination was associated with lower pneumonia and all�?cause mortality"/>
 <result pre="pneumococcal polysaccharide vaccination and influenza vaccination was associated with lower" exact="pneumonia" post="and all�?cause mortality than influenza vaccination alone.71 Chang et"/>
 <result pre="vaccination was associated with lower pneumonia and all�?cause mortality than" exact="influenza" post="vaccination alone.71 Chang et al72 analyzed 24 429 elderly"/>
 <result pre="75 years in Taiwan, China, and reported that compared with" exact="influenza" post="vaccination alone, additional pneumococcal vaccination yielded additive reductions of"/>
 <result pre="inpatient expenditure. Nichol73 followed up elderly people diagnosed with chronic" exact="lung disease" post="for three influenza seasons. In that study, influenza vaccination"/>
 <result pre="up elderly people diagnosed with chronic lung disease for three" exact="influenza" post="seasons. In that study, influenza vaccination alone was associated"/>
 <result pre="chronic lung disease for three influenza seasons. In that study," exact="influenza" post="vaccination alone was associated with substantial reductions in hospitalization"/>
 <result pre="In summary, previous studies have shown that simultaneous administration of" exact="influenza" post="and pneumococcal vaccines in elderly people is effective and"/>
 <result pre="immunocompetent adults aged ≥ 65 years. Those who have chronic" exact="cardiovascular disease" post="(excluding hypertension), chronic lung disease, chronic liver disease, diabetes,"/>
 <result pre="years. Those who have chronic cardiovascular disease (excluding hypertension), chronic" exact="lung disease," post="chronic liver disease, diabetes, and/or alcohol or smoking habits"/>
 <result pre="have chronic cardiovascular disease (excluding hypertension), chronic lung disease, chronic" exact="liver disease," post="diabetes, and/or alcohol or smoking habits should receive another"/>
 <result pre="given priority: chronic illness, such as chronic pulmonary disease (eg," exact="chronic obstructive pulmonary disease," post="asthma, bronchiectasis); chronic cardiovascular disease (eg, congestive heart failure"/>
 <result pre="pulmonary disease (eg, chronic obstructive pulmonary disease, asthma, bronchiectasis); chronic" exact="cardiovascular disease" post="(eg, congestive heart failure or cardiomyopathies, but excluding hypertension);"/>
 <result pre="chronic obstructive pulmonary disease, asthma, bronchiectasis); chronic cardiovascular disease (eg," exact="congestive heart failure" post="or cardiomyopathies, but excluding hypertension); chronic liver disease (cirrhosis);"/>
 <result pre="(eg, congestive heart failure or cardiomyopathies, but excluding hypertension); chronic" exact="liver disease" post="(cirrhosis); cochlear implants; diabetes mellitus; cerebrospinal fluid leaks; alcoholism;"/>
 <result pre="cardiomyopathies, but excluding hypertension); chronic liver disease (cirrhosis); cochlear implants;" exact="diabetes mellitus;" post="cerebrospinal fluid leaks; alcoholism; functional or anatomic asplenia (congenital"/>
 <result pre="reduced immune function (such as congenital or acquired immunodeficiencies, HIV," exact="nephrotic syndrome," post="chronic renal failure, generalized malignancy, multiple myeloma, leukemia, lymphomas,"/>
 <result pre="acquired immunodeficiencies, HIV, nephrotic syndrome, chronic renal failure, generalized malignancy," exact="multiple myeloma," post="leukemia, lymphomas, Hodgkin’s disease, solid organ transplantation and bone"/>
 <result pre="References REFERENCES 1KajiM, WatanabeA, AizawaH. Differences in clinical features between" exact="influenza" post="A H1N1, A H3N2, and B in adult patients."/>
 <result pre="2GoldsteinE, CobeyS, TakahashiS, MillerJC, LipsitchM. Predicting the epidemic sizes of" exact="influenza" post="A/H1N1, A/H3N2, and B: a statistical method. PLoS Medicine."/>
 <result pre="cities, 2003�?2008. Bull World Health Organ. 2012;90(4):279�?288.22511824 4PleschkaS. Overview of" exact="influenza" post="viruses In: RichtJA, WebbyRJ, eds. Swine Influenza, Vol. 370Berlin:"/>
 <result pre="Berlin; 2013:1�?20. 5YuHJ, AlonsoWJ, FengLZ, et al. Characterization of regional" exact="influenza" post="seasonality patterns in China and implications for vaccination strategies:"/>
 <result pre="8YuH, HuangJ, HuaiY, et al. The substantial hospitalization burden of" exact="influenza" post="in central China: surveillance for severe, acute respiratory infection,"/>
 <result pre="in central China: surveillance for severe, acute respiratory infection, and" exact="influenza" post="viruses, 2010�?2012. Influenza Other Respir Viruses. 2014;8(1):53�?65.24209711 9YangJ, JitM,"/>
 <result pre="a retrospective survey. Infect Dis Poverty. 2015;4:44.26445412 10FukumiH. History of" exact="influenza" post="vaccine. Uirusu. 1985;35(2):107�?122.3010561 11TriccoAC, ChitA, SoobiahC, et al. Comparing"/>
 <result pre="influenza vaccine. Uirusu. 1985;35(2):107�?122.3010561 11TriccoAC, ChitA, SoobiahC, et al. Comparing" exact="influenza" post="vaccine efficacy against mismatched and matched strains: a systematic"/>
 <result pre="BMC Med. 2013;11:153.23800265 12DiazGranadosCA, DunningAJ, JordanovE, et al. High�?dose trivalent" exact="influenza" post="vaccine compared to standard dose vaccine in elderly adults:"/>
 <result pre="ZhangT, et al. Technical guidelines for the application of seasonal" exact="influenza" post="vaccine in China (2014�?2015). Chin J Epidemiol. 2014;35(12):1295�?1319. 14CoxRJ,"/>
 <result pre="early humoral immune response in peripheral blood following parenteral inactivated" exact="influenza" post="vaccination. Vaccine. 1994;12(11):993�?999.7975853 15BrokstadKA, CoxRJ, OlofssonJ, JonssonR, HaaheimLR. Parenteral"/>
 <result pre="influenza vaccination. Vaccine. 1994;12(11):993�?999.7975853 15BrokstadKA, CoxRJ, OlofssonJ, JonssonR, HaaheimLR. Parenteral" exact="influenza" post="vaccination induces a rapid systemic and local immune response."/>
 <result pre="Dis. 1995;171(1):198�?203.7798664 16JamesonJ, CruzJ, EnnisFA. Human cytotoxic T�?lymphocyte repertoire to" exact="influenza" post="A viruses. J Virol. 1998;72(11):8682�?8689.9765409 17DiazGranadosCA, DunningAJ, KimmelM, et"/>
 <result pre="17DiazGranadosCA, DunningAJ, KimmelM, et al. Efficacy of high�?dose versus standard�?dose" exact="influenza" post="vaccine in older adults. N Engl J Med. 2014;371(7):635�?645.25119609"/>
 <result pre="al. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated" exact="influenza" post="virus vaccines�?1978. Rev Infect Dis. 1983;5(4):737�?747.6622888 19XinY, LiuM. Meta"/>
 <result pre="1983;5(4):737�?747.6622888 19XinY, LiuM. Meta analysis on the effectiveness of inactivated" exact="influenza" post="vaccine. Chin J Epidemiol. 2009;30(4):368�?370. 20LiuM, LiuGF, WangY, et"/>
 <result pre="WangY, et al. Study on the effectiveness and cost�?benefit of" exact="influenza" post="vaccine elderly population in Beijing city. Chin J Epidemiol."/>
 <result pre="J Epidemiol. 2005;26(6):412�?416. 21NicholKL, NordinJD, NelsonDB, MulloolyJP, HakE. Effectiveness of" exact="influenza" post="vaccine in the community�?dwelling elderly. N Engl J Med."/>
 <result pre="Influenza vaccination and reduction in hospitalizations for cardiac disease and" exact="stroke" post="among the elderly. N Engl J Med. 2003;348(14):1322�?1332.12672859 24DongZY,"/>
 <result pre="review. Vaccine. 2013;31(46):5339�?5348.24055351 26WangI�?K, LinC�?L, ChangY�?C, et al. Effectiveness of" exact="influenza" post="vaccination in elderly diabetic patients: a retrospective cohort study."/>
 <result pre="2013;31(4):718�?724.23153445 27MargolisKL, NicholKL, PolandGA, PluharRJ. Frequency of adverse reactions to" exact="influenza" post="vaccine in the elderly: a randomized, placebo�?controlled trial. JAMA."/>
 <result pre="1990;264(9):1139�?1141.2200894 28GovaertTM, DinantGJ, AretzK, MasurelN, SprengerMJ, KnottnerusJA. Adverse reactions to" exact="influenza" post="vaccine in elderly people: randomised double blind placebo controlled"/>
 <result pre="1993;307(6910):988�?990.8241913 29NicholKL, MargolisKL, LindA, et al. Side effects associated with" exact="influenza" post="vaccination in healthy working adults. A randomized, placebo�?controlled trial."/>
 <result pre="1996;156(14):1546�?1550.8687262 30BridgesCB, ThompsonWW, MeltzerMI, et al. Effectiveness and cost�?benefit of" exact="influenza" post="vaccination of healthy working adults: a randomized controlled trial."/>
 <result pre="2012;87(47):461�?476.23210147 32FioreAE, UyekiTM, BroderK, et al. Prevention and control of" exact="influenza" post="with vaccines: recommendations of the Advisory Committee on Immunization"/>
 <result pre="et al. The Guillain�?Barré syndrome and the 1992�?1993 and 1993�?1994" exact="influenza" post="vaccines. N Engl J Med. 1998;339(25):1797�?1802.9854114 34JuurlinkDN, StukelTA, KwongJ,"/>
 <result pre="Med. 1998;339(25):1797�?1802.9854114 34JuurlinkDN, StukelTA, KwongJ, et al. Guillain�?Barré syndrome after" exact="influenza" post="vaccination in adults: a population�?based study. Arch Intern Med."/>
 <result pre="36VellozziC, BurwenDR, DobardzicA, BallR, WaltonK, HaberP. Safety of trivalent inactivated" exact="influenza" post="vaccines in adults: background for pandemic influenza vaccine safety"/>
 <result pre="of trivalent inactivated influenza vaccines in adults: background for pandemic" exact="influenza" post="vaccine safety monitoring. Vaccine. 2009;27(15):2114�?2120.19356614 37YangJ, AtkinsKE, FengL, et"/>
 <result pre="safety monitoring. Vaccine. 2009;27(15):2114�?2120.19356614 37YangJ, AtkinsKE, FengL, et al. Seasonal" exact="influenza" post="vaccination in China: Landscape of diverse regional reimbursement policy,"/>
 <result pre="impact analysis. Vaccine. 2016;34(47):5724�?5735.27745951 38ZhouL, SuQ, XuZ, et al. Seasonal" exact="influenza" post="vaccination coverage rate of target groups in selected cities"/>
 <result pre="One. 2013;8(9):e73724.24040041 39ZhangY, MuscatelloDJ, WangQ, YangP, WuJ, MacIntyreCR. Overview of" exact="influenza" post="vaccination policy in Beijing, China: current status and future"/>
 <result pre="2017;38(3):366�?379.28512300 40collab: Hospital Influenza Workgroup Singapore . Management of novel" exact="influenza" post="epidemics in Singapore: consensus recommendations from the Hospital Influenza"/>
 <result pre="2004;27(3):155�?160. 49LiuH, ZhangTT, WuBY, et al. Clinical analysis of community�?acquired" exact="pneumonia" post="in the elderly. Chin J Intern Med. 2007;46(10):810�?814. 50SunHL,"/>
 <result pre="on the pathogenic agents in 665 adult patients with community�?acquired" exact="pneumonia" post="in cities of China. Chin J Tuberc Respir Dis."/>
 <result pre="al. Effectiveness of the 23�?valent pneumococcal polysaccharide vaccine against community�?acquired" exact="pneumonia" post="in the general population aged ≥60 years: 3 years"/>
 <result pre="NiedermanMS, et al. Efficacy of 23�?valent pneumococcal vaccine in preventing" exact="pneumonia" post="and improving survival in nursing home residents: double blind,"/>
 <result pre="2016;34(50):6158�?6165.27838068 71ZhangYY, TangXF, DuCH, WangBB, BiZW, DongBR. Comparison of dual" exact="influenza" post="and pneumococcal polysaccharide vaccination with influenza vaccination alone for"/>
 <result pre="DongBR. Comparison of dual influenza and pneumococcal polysaccharide vaccination with" exact="influenza" post="vaccination alone for preventing pneumonia and reducing mortality among"/>
 <result pre="and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing" exact="pneumonia" post="and reducing mortality among the elderly: a meta�?analysis. Human"/>
 <result pre="72ChangYC, ChouYJ, LiuJY, YehTF, HuangN. Additive benefits of pneumococcal and" exact="influenza" post="vaccines among elderly persons aged 75 years or older"/>
 <result pre="comparative study. J Infect. 2012;65(3):231�?238.22561486 73NicholKL. The additive benefits of" exact="influenza" post="and pneumococcal vaccinations during influenza seasons among elderly persons"/>
 <result pre="73NicholKL. The additive benefits of influenza and pneumococcal vaccinations during" exact="influenza" post="seasons among elderly persons with chronic lung disease. Vaccine."/>
 <result pre="pneumococcal vaccinations during influenza seasons among elderly persons with chronic" exact="lung disease." post="Vaccine. 1999;17(suppl 1):S91�?S93.10471189 74GrilliG, FuianoL, BiasioLR, et al. Simultaneous"/>
 <result pre="disease. Vaccine. 1999;17(suppl 1):S91�?S93.10471189 74GrilliG, FuianoL, BiasioLR, et al. Simultaneous" exact="influenza" post="and pneumococcal vaccination in elderly individuals. Eur J Epidemiol."/>
 <result pre="Health Care. 2015;23(3):89. 79ZhuB, HuangRN, YangRP, et al. Investigation on" exact="pneumonia" post="vaccination coverage and influencing factors among elderly population with"/>
</results>
